A Phase 2 interventional study of S (+) - Ibuprofen and Ibuvix® - ibuprofen in Osteoarthritis, sponsored by Apsen Farmaceutica S.A.. Completed at 1 site in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Apsen Farmaceutica S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Osteoarthritis with a site in Brazil — 3 open to participants now, 3 under way, 2 of them phase 3. Osteoarthritis · Brazil.
Among the 57 studies in Osteoarthritis with a site in Brazil, this one is the 9th largest by enrollment of the 56 interventional ones that give a count, is the only one that started in 2022, is one of 6 in phase 2, and was the 50th registered.
2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →3 of the 57 studies in Osteoarthritis with a site in Brazil are open now. Recruiting first, the newest first:
Instituto Nacional de Traumatologia e Ortopedia · Sites in Brazil
Ages 40–60
Instituto Nacional de Traumatologia e Ortopedia · Sites in Brazil
Ages 40–60
D'Or Institute for Research and Education · Sites in Brazil
Ages 50–75
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 8 · Phase 4 9
First in 2004; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 71 across the 56 interventional studies, 30 across the 1 observational. Of the 40 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 57 have an industry lead sponsor. The 10 most frequent:
Apsen Farmaceutica S.A. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Apsen Farmaceutica S.A. has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Osteoarthritis with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of S (+) - ibuprofen compared to an active treatment for pain control in individuals diagnosed with osteoarthritis.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.
Drug: S (+) - Ibuprofen
Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.
Drug: Ibuvix® - ibuprofen
S (+) - Ibuprofen + placebo of Ibuvix®
Ibuvix® + placebo of S(+) - Ibuprofen
Mean reduction of pain measured by the WOMAC Osteoarthritis Index (pain)
Time frame: Baseline (day 0) and Week 4 (day 28)
Patient Global Impression of Improvement-I (PGI-I)
Time frame: Week 4 (day 28)
Proportion of participants among the groups to discontinue the trial due to treatment non-tolerability
Time frame: From Baseline (day 0) to Week 4 (day 28)
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2022 to primary completion in Jun 2023, 10 months.
Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 10 months is below that.
Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Apsen Farmaceutica S.A.